AU2015236045B2 - Methods and genetic systems for cell engineering - Google Patents

Methods and genetic systems for cell engineering Download PDF

Info

Publication number
AU2015236045B2
AU2015236045B2 AU2015236045A AU2015236045A AU2015236045B2 AU 2015236045 B2 AU2015236045 B2 AU 2015236045B2 AU 2015236045 A AU2015236045 A AU 2015236045A AU 2015236045 A AU2015236045 A AU 2015236045A AU 2015236045 B2 AU2015236045 B2 AU 2015236045B2
Authority
AU
Australia
Prior art keywords
gene
sequence
target
cells
engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015236045A
Other languages
English (en)
Other versions
AU2015236045A1 (en
Inventor
Patrick Boyle
Reshma P. Shetty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ginkgo Bioworks Inc
Original Assignee
Ginkgo Bioworks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54196352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015236045(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ginkgo Bioworks Inc filed Critical Ginkgo Bioworks Inc
Publication of AU2015236045A1 publication Critical patent/AU2015236045A1/en
Application granted granted Critical
Publication of AU2015236045B2 publication Critical patent/AU2015236045B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2015236045A 2014-03-25 2015-03-25 Methods and genetic systems for cell engineering Ceased AU2015236045B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461970024P 2014-03-25 2014-03-25
US61/970,024 2014-03-25
PCT/US2015/022508 WO2015148680A1 (en) 2014-03-25 2015-03-25 Methods and genetic systems for cell engineering

Publications (2)

Publication Number Publication Date
AU2015236045A1 AU2015236045A1 (en) 2016-10-13
AU2015236045B2 true AU2015236045B2 (en) 2021-09-23

Family

ID=54196352

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015236045A Ceased AU2015236045B2 (en) 2014-03-25 2015-03-25 Methods and genetic systems for cell engineering

Country Status (7)

Country Link
US (1) US20170173086A1 (https=)
EP (1) EP3122870B1 (https=)
JP (2) JP2017512500A (https=)
AU (1) AU2015236045B2 (https=)
CA (1) CA2943775A1 (https=)
DK (1) DK3122870T3 (https=)
WO (1) WO2015148680A1 (https=)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6261500B2 (ja) 2011-07-22 2018-01-17 プレジデント アンド フェローズ オブ ハーバード カレッジ ヌクレアーゼ切断特異性の評価および改善
US10053719B2 (en) 2013-03-13 2018-08-21 Gen9, Inc. Compositions and methods for synthesis of high fidelity oligonucleotides
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
WO2015066119A1 (en) 2013-10-30 2015-05-07 North Carolina State University Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
AU2014346559B2 (en) 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US10787654B2 (en) 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
WO2015148680A1 (en) 2014-03-25 2015-10-01 Ginkgo Bioworks, Inc. Methods and genetic systems for cell engineering
US11439712B2 (en) 2014-04-08 2022-09-13 North Carolina State University Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3633032A3 (en) 2014-08-28 2020-07-29 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
CN107667173A (zh) 2015-05-06 2018-02-06 斯尼普技术有限公司 改变微生物种群和改善微生物群
KR20220139447A (ko) 2015-05-29 2022-10-14 노쓰 캐롤라이나 스테이트 유니버시티 크리스퍼 핵산을 사용하여 박테리아, 고세균, 조류 및 효모를 스크리닝하는 방법
KR102468240B1 (ko) 2015-06-15 2022-11-17 노쓰 캐롤라이나 스테이트 유니버시티 핵산 및 rna-기반 항미생물제를 효율적으로 전달하기 위한 방법 및 조성물
WO2017058751A1 (en) 2015-09-28 2017-04-06 North Carolina State University Methods and compositions for sequence specific antimicrobials
JP7109784B2 (ja) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したＣａｓ９蛋白質
JP6821598B2 (ja) 2015-12-07 2021-01-27 ザイマージェン インコーポレイテッド Ｃｏｒｙｎｅｂａｃｔｅｒｉｕｍ ｇｌｕｔａｍｉｃｕｍ由来のプロモーター
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
US11542466B2 (en) 2015-12-22 2023-01-03 North Carolina State University Methods and compositions for delivery of CRISPR based antimicrobials
AU2016380351B2 (en) 2015-12-29 2023-04-06 Monsanto Technology Llc Novel CRISPR-associated transposases and uses thereof
CN115919906A (zh) 2016-03-04 2023-04-07 加利福尼亚大学董事会 微生物聚生体及其用途
AU2017252409B2 (en) 2016-04-20 2023-08-24 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for nucleic acid expression and protein secretion in bacteroides
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
EP3478833A4 (en) 2016-06-30 2019-10-02 Zymergen, Inc. METHOD FOR PRODUCING A BACTERIAL HEMOGLOBIN LIBRARY AND ITS USE
JP2019519241A (ja) 2016-06-30 2019-07-11 ザイマージェン インコーポレイテッド グルコース透過酵素ライブラリーを生成するための方法およびその使用
KR102547316B1 (ko) 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018071841A1 (en) * 2016-10-14 2018-04-19 The Forsyth Institute Compositions and methods for evading bacterial defense mechanisms
EP3526320A1 (en) 2016-10-14 2019-08-21 President and Fellows of Harvard College Aav delivery of nucleobase editors
WO2018112194A1 (en) 2016-12-15 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11224624B2 (en) * 2017-02-14 2022-01-18 California Institute Of Technology Modulation of microbial synthesis of 4-etylphenol and 4-ethylphenyl sulfate in behavior and disease
JP2020510038A (ja) 2017-03-09 2020-04-02 プレジデント アンド フェローズ オブ ハーバード カレッジ がんワクチン
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
AU2019253714A1 (en) 2018-04-10 2020-11-26 Siolta Therapeutics, Inc. Microbial consortia
EP3797160A1 (en) 2018-05-23 2021-03-31 The Broad Institute Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020072250A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression
US12264330B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
WO2020072248A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system
WO2020072253A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for screening for variant cells
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020118435A1 (en) * 2018-12-11 2020-06-18 University Of Western Ontario Cis conjugative plasmid system
CN109652570A (zh) * 2019-01-16 2019-04-19 中国人民解放军总医院 微生物在鉴别和/或区分不同种族个体中的应用
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020163655A1 (en) 2019-02-06 2020-08-13 Fred Hutchinson Cancer Research Center Minicircle producing bacteria engineered to differentially methylate nucleic acid molecules therein
CA3132197A1 (en) 2019-03-07 2020-09-10 The Trustees Of Columbia University In The City Of New York Rna-guided dna integration using tn7-like transposons
JP7657726B2 (ja) 2019-03-19 2025-04-07 ザ ブロード インスティテュート，インコーポレーテッド 編集ヌクレオチド配列を編集するための方法および組成物
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
GB201906668D0 (en) * 2019-05-12 2019-06-26 Folium Food Science Ltd Antibacterial agents
US20210095273A1 (en) * 2019-09-30 2021-04-01 Sigma-Aldrich Co. Llc Modulation of microbiota compositions using targeted nucleases
KR20220108765A (ko) 2019-10-07 2022-08-03 시올타 테라퓨틱스, 인크. 치료용 약학 조성물
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021119594A1 (en) * 2019-12-13 2021-06-17 The Regents Of The University Of California Reducing antibiotic resistance in bacteria using pro-active genetics
WO2021127209A1 (en) * 2019-12-17 2021-06-24 Sigma-Aldrich Co. Llc Genome editing in bacteroides
DE112021002672T5 (de) 2020-05-08 2023-04-13 President And Fellows Of Harvard College Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
CN112029699B (zh) * 2020-11-04 2021-06-08 中国农业科学院北京畜牧兽医研究所 一种基于内源CRISPR-Cas系统的丁酸梭菌基因编辑系统及其应用
US11851664B2 (en) * 2020-12-24 2023-12-26 Oakbio, Inc. Methods for producing biochemicals using enzyme genes derived from a strain of Brevundimonas, and compositions made thereby
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0487159A1 (en) * 1990-11-23 1992-05-27 Unilever N.V. A food-grade vector suitable for transforming a food-grade host cell, use of said vector for transforming food-grade host cells, and use of said transformed cells in biotransformation processes
US7005561B2 (en) 2000-03-08 2006-02-28 University Of Georgia Research Foundation, Inc. Arabitol or ribitol as positive selectable markers
JP2005519872A (ja) * 2001-11-12 2005-07-07 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー サルモネラ・ワクチン
WO2005017172A1 (en) * 2003-08-14 2005-02-24 Dsm Ip Assets B.V. Microbial production of l-ascorbic acid
FI116068B (fi) 2003-09-15 2005-09-15 Fit Biotech Oyj Plc Uusi selektiojärjestelmä, siinä käyttökelpoinen vektori, bakteerisolukantoja sekä menetelmä solujen valikoimiseksi
AU2008317000B2 (en) * 2007-10-26 2014-10-23 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
JP5783503B2 (ja) * 2008-09-03 2015-09-24 国立研究開発法人農業・食品産業技術総合研究機構 外来遺伝子を導入しない、非遺伝子組換えの遺伝子欠損株とその作製および選抜方法
KR102262704B1 (ko) * 2009-08-11 2021-06-09 상가모 테라퓨틱스, 인코포레이티드 표적화 변형에 대한 동형접합성 유기체
WO2011101696A1 (en) * 2010-02-18 2011-08-25 Cellectis Improved meganuclease recombination system
CN103261213A (zh) 2010-10-20 2013-08-21 杜邦营养生物科学有限公司 乳球菌CRISPR-Cas序列
EP3241902B1 (en) * 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
WO2015034872A2 (en) 2013-09-05 2015-03-12 Massachusetts Institute Of Technology Tuning microbial populations with programmable nucleases
WO2015148680A1 (en) 2014-03-25 2015-10-01 Ginkgo Bioworks, Inc. Methods and genetic systems for cell engineering

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIKARD DAVID ET AL, "CRISPR Interference Can Prevent Natural Transformation and Virulence Acquisition during In Vivo Bacterial Infection", CELL HOST & MICROBE, (2012-08-16), vol. 12, no. 2, pages 177 - 186 *
R. SAPRANAUSKAS ET AL, "The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli", NUCLEIC ACIDS RESEARCH, (2011-08-03), vol. 39, no. 21, doi:10.1093/nar/gkr606, ISSN 0305-1048, pages 9275 - 9282 *

Also Published As

Publication number Publication date
AU2015236045A1 (en) 2016-10-13
JP2017512500A (ja) 2017-05-25
EP3122870B1 (en) 2022-06-29
WO2015148680A1 (en) 2015-10-01
CA2943775A1 (en) 2015-10-01
DK3122870T3 (da) 2022-09-12
EP3122870A1 (en) 2017-02-01
JP2021000092A (ja) 2021-01-07
EP3122870A4 (en) 2017-08-30
US20170173086A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
AU2015236045B2 (en) Methods and genetic systems for cell engineering
CN110551713B (zh) 用于修饰梭状芽孢杆菌属细菌的优化的遗传工具
KR20210149060A (ko) Tn7-유사 트랜스포존을 사용한 rna-유도된 dna 통합
CN108546712B (zh) 一种利用CRISPR/LbCpf1系统实现目的基因在植物中同源重组的方法
KR20210149686A (ko) 유전자 편집에 유용한 폴리펩티드 및 사용 방법
KR101982360B1 (ko) 콤팩트 tale-뉴클레아제의 발생 방법 및 이의 용도
KR102266691B1 (ko) 항원 전달 플랫폼
DK2663645T3 (da) Gærstammer, der er modificeret til produktion af ethanol fra glycerol
AU2024205703A1 (en) Wheat stem rust resistance genes and methods of use
CA2763792C (en) Expression cassettes derived from maize
BRPI0806354A2 (pt) plantas oleaginosas transgências, sementes, óleos, produtos alimentìcios ou análogos a alimento, produtos alimentìcios medicinais ou análogos alimentìcios medicinais, produtos farmacêuticos, bebidas fórmulas para bebês, suplementos nutricionais, rações para animais domésticos, alimentos para aquacultura, rações animais, produtos de sementes inteiras, produtos de óleos misturados, produtos, subprodutos e subprodutos parcialmente processados
KR20230165368A (ko) Cpf1 또는 csm1을 사용하여 게놈을 변형하기 위한 조성물 및 방법
KR20140113997A (ko) 부탄올 생성을 위한 유전자 스위치
DK2931918T5 (en) PROCEDURE FOR IDENTIFYING A CELL WITH INCREASED CONCENTRATION OF A PARTICULAR METABOLIT COMPARED TO THE SIMILAR WILD TYPE CELL .....
KR20140092759A (ko) 숙주 세포 및 아이소부탄올의 제조 방법
DK3158065T3 (en) NUCLEIC ACIDS AND VECTORS FOR USE WITH METHANOTROPHIC BACTERIES
CN101001951B (zh) 分离转录终止序列的方法
CN112469823A (zh) 布鲁顿氏酪氨酸激酶的基于talen和基于crispr/cas的基因编辑
CN113614229B (zh) 遗传修饰的梭菌属细菌、其制备和用途
CN114746549A (zh) 加快细胞内生物学设计的模块化、无细胞蛋白质表达载体
CN114836459A (zh) 一种胞嘧啶碱基编辑系统及其应用
US11236401B2 (en) Sensors for detection and quantification of microbiological protein secretion
CN113999317B (zh) 激发机体抗非洲猪瘟感染的融合基因及其编码蛋白和应用
KR20160090906A (ko) 에레모테시움의 발효를 통한 리보플라빈의 더 높은 생성을 위한 베타-산화 경로의 효소를 엔코딩하는 유전자 및 지방산 수송체 유전자의 과-발현
TW202403048A (zh) 用於治療龐貝症之具有訊號肽修飾之以密碼子最佳化核酸編碼α-葡萄糖苷酶(GAA)之治療性腺相關病毒

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired